MannKind (MNKD) will acquire scPharma (SCPH) in a $360 million deal, offering $5.35/share in cash plus up to $1 in milestones. Analysts issued mixed calls: Craig-Hallum and Maxim cut SCPH to Hold, while HC Wainwright backed MNKD with a $9 target. The deal gives MannKind access to Furoscix, a heart and kidney therapy with $10 billion US market potential.